Aflibercept solution (Eylea) for visual impairment due to choroidal neovascularisation secondary to pathological myopia
NIHR HSRIC
Record ID 32016000417
English
Authors' objectives:
Extreme short-sightedness may increase the risk of developing several eye conditions and is called pathological myopia. One of these eye conditions is called choroidal neovascularisation, which often leads to problems with a patient's sight and can eventually result in blindness.
Aflibercept is a new drug for the treatment of choroidal neovascularisation caused by pathological myopia. It is given as an injection into the eye.
If aflibercept is licenced for use in the UK, it could be a new treatment option for patients with this condition, which may improve their vision and be more convenient than current treatment options.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/aflibercept-solution-eylea-for-visual-impairment-due-to-choroidal-neovascularisation-secondary-to-pathological-myopia/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Choroidal Neovascularization
- Myopia, Degenerative
- Pharmaceutical Solutions
- Receptors, Vascular Endothelial Growth Factor
- Recombinant Fusion Proteins
- Solutions
- Vision Disorders
- Angiogenesis Inhibitors
- Intravitreal Injections
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.